MicroRNA-21 and microRNA-29a modulate the expression of collagen in dermal fibroblasts of patients with systemic sclerosis

References

• Hua-Huy T, Dinh-Xuan AT. Cellular and molecular mechanisms in the pathophysiology of systemic sclerosis. Pathol-Biol. 2015;63:61–68.
   PubMedGoogle Scholar
• Sakkas LI. New developments in the pathogenesis of systemic sclerosis. Autoimmunity 2005;38:113–116.
   PubMed Web of Science ®Google Scholar
• Cottrell TR, Wise RA, Wigley FM, et al. The degree of skin involvement identifies distinct lung disease outcomes and survival in systemic sclerosis. Ann Rheum Dis. 2014;73:1060–1066.
   PubMed Web of Science ®Google Scholar
• Katsumoto TR, Whitfield ML, Connolly MK. The pathogenesis of systemic sclerosis. Annu Rev Pathol. 2011;6:509–537.
   PubMed Web of Science ®Google Scholar
• Fett N. Scleroderma: nomenclature, etiology, pathogenesis, prognosis, and treatments: facts and controversies. Clin Dermatol. 2013;31:432–437.
   PubMed Web of Science ®Google Scholar
• Zimmermann AF, Pizzichini MM. Update on etiopathogenesis of systemic sclerosis. Revist Bras Reumatol. 2013;53:516–524.
   PubMedGoogle Scholar
• Rezaei R, Aslani S, Dashti N, et al. Genetic implications in the pathogenesis of systemic sclerosis. Int J Rheum Dis. 2018;21:1478–1486.
   PubMed Web of Science ®Google Scholar
• Muller-Ladner U, Distler O, Ibba-Manneschi L, et al. Mechanisms of vascular damage in systemic sclerosis. Autoimmunity 2009;42:587–595.
   PubMed Web of Science ®Google Scholar
• Feghali CA, Bost KL, Boulware DW, et al. Control of IL-6 expression and response in fibroblasts from patients with systemic sclerosis. Autoimmunity 1994;17:309–318.
   PubMed Web of Science ®Google Scholar
• Garrett SM, Frost DB, Feghali-Bostwick C. The mighty fibroblast and its utility in scleroderma research. J Scleroderma Related Disord. 2017;2:69–134.
   PubMed Web of Science ®Google Scholar
• Gharibdoost F, Faezi ST, Khorram Khorshid H, et al. Efficacy and safety of ANGIPARS for the treatment of skin manifestations of scleroderma: a phase 2 clinical trial. Rheum Res. 2016;1:3–9.
   Google Scholar
• Varga J, Pasche B. Transforming growth factor beta as a therapeutic target in systemic sclerosis. Nat Rev Rheumatol. 2009;5:200–206.
   PubMed Web of Science ®Google Scholar
• Trojanowska M. What did we learn by studying scleroderma fibroblasts? Clin Exp Rheumatol. 2004;22:S59–S63.
   PubMed Web of Science ®Google Scholar
• Friedman RC, Burge FK-H, Bartel CB. Most mammalian mRNAs are conserved targets of microRNAs. Geome Res. 2009;19:92–105.
   Google Scholar
• Vettori S, Gay S, Distler O. Role of microRNAs in fibrosis. Open Rheumatol J. 2012;6:130–139.
   PubMedGoogle Scholar
• Jiang X, Tsitsiou E, Herrick SE, et al. MicroRNAs and the regulation of fibrosis. FEBS J. 2010;277:2015–2021.
   PubMed Web of Science ®Google Scholar
• O'Reilly S. miRNA-29a in systemic sclerosis: a valid target. Autoimmunity 2015;48:511–512.
   PubMed Web of Science ®Google Scholar
• Broen JC, Radstake TR, Rossato M. The role of genetics and epigenetics in the pathogenesis of systemic sclerosis. Nat Rev Rheumatol. 2014;10:671–681.
   PubMed Web of Science ®Google Scholar
• Altorok N, Kahaleh B. Epigenetics and systemic sclerosis. Semin Immunopathol. 2015;37:453–462.
   PubMed Web of Science ®Google Scholar
• Sato F, Tsuchiya S, Meltzer SJ, et al. MicroRNAs and epigenetics. FEBS J. 2011;278:1598–1609.
   PubMed Web of Science ®Google Scholar
• Aslani S, Sobhani S, Gharibdoost F, et al. Epigenetics and pathogenesis of systemic sclerosis; the ins and outs. Human Immunol. 2018;79:178–187.
   PubMed Web of Science ®Google Scholar
• Zhou B, Zuo XX, Li YS, et al. Integration of microRNA and mRNA expression profiles in the skin of systemic sclerosis patients. Sci Rep. 2017;7:42899.
   PubMed Web of Science ®Google Scholar
• Zhu H, Li Y, Qu S, et al. MicroRNA expression abnormalities in limited cutaneous scleroderma and diffuse cutaneous scleroderma. J Clin Immunol. 2012;32:514–522.
   PubMed Web of Science ®Google Scholar
• Li H, Yang R, Fan X, et al. MicroRNA array analysis of microRNAs related to systemic scleroderma. Rheumatol Int. 2012;32:307–313.
   PubMed Web of Science ®Google Scholar
• Thannickal VJ, Lee DY, White ES, et al. Myofibroblast differentiation by transforming growth factor-beta1 is dependent on cell adhesion and integrin signaling via focal adhesion kinase. J Biol Chem. 2003;278:12384–12389.
   PubMed Web of Science ®Google Scholar
• Makino K, Jinnin M, Hirano A, et al. The downregulation of microRNA let-7a contributes to the excessive expression of type I collagen in systemic and localized scleroderma. J Immunol. 2013;190:3905–3915.
   PubMed Web of Science ®Google Scholar
• Zeng X, C, Huang, L, Senavirathna, et al. miR-27b inhibits fibroblast activation via targeting TGFbeta signaling pathway. BMC Cell Biol. 2017;18:9.
   PubMed Web of Science ®Google Scholar
• Zhu H, Luo H, Li Y, et al. MicroRNA-21 in scleroderma fibrosis and its function in TGF-beta-regulated fibrosis-related genes expression. J Clin Immunol. 2013;33:1100–1109.
   PubMed Web of Science ®Google Scholar
• Maurer B, Stanczyk J, Jungel A, et al. MicroRNA-29, a key regulator of collagen expression in systemic sclerosis. Arthritis Rheum. 2010;62:1733–1743.
   PubMed Web of Science ®Google Scholar
• Christmann RB, Wooten A, Sampaio-Barros P, et al. miR-155 in the progression of lung fibrosis in systemic sclerosis. Arthritis Res Ther. 2016;18:155.
   PubMed Web of Science ®Google Scholar
• Varga J, Hinchcliff M. Connective tissue diseases: systemic sclerosis: beyond limited and diffuse subsets? Nat Rev Rheumatol. 2014;10:200–202.
   PubMedGoogle Scholar
• Zhu H, Luo H, Zuo X. MicroRNAs: their involvement in fibrosis pathogenesis and use as diagnostic biomarkers in scleroderma. Exp Mol Med. 2013;45:e41.
   PubMed Web of Science ®Google Scholar
• Kriegel AJ, Liu Y, Fang Y, et al. The miR-29 family: genomics, cell biology, and relevance to renal and cardiovascular injury. Physiol Genomics. 2012;44:237–244.
   PubMed Web of Science ®Google Scholar
• Cushing L, Kuang PP, Qian J, et al. miR-29 is a major regulator of genes associated with pulmonary fibrosis. Am J Respir Cell Mol Biol. 2011;45:287–294.
   PubMed Web of Science ®Google Scholar
• Liu Y, Taylor NE, Lu L, et al. Renal medullary microRNAs in Dahl salt-sensitive rats: miR-29b regulates several collagens and related genes. Hypertension (Dallas, TX.: 1979). 2010;55:974–982.
   PubMed Web of Science ®Google Scholar
• Roderburg C, Urban GW, Bettermann K, et al. Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. Hepatology (Baltimore, MD). 2011;53:209–218.
   PubMed Web of Science ®Google Scholar
• Xiao J, Meng XM, Huang XR, et al. miR-29 inhibits bleomycin-induced pulmonary fibrosis in mice. Mol Ther. 2012;20:1251–1260.
   PubMed Web of Science ®Google Scholar
• Qin W, Chung AC, Huang XR, et al. TGF-beta/Smad3 signaling promotes renal fibrosis by inhibiting miR-29. JASN. 2011;22:1462–1474.
   Web of Science ®Google Scholar
• van Rooij E, Sutherland LB, Thatcher JE, et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci USA. 2008;105:13027–13032.
   PubMed Web of Science ®Google Scholar
• Ma X, DJ Conklin, F, Li Z, et al. The oncogenic microRNA miR-21 promotes regulated necrosis in mice. Nat Commun. 2015;6:7151.
   PubMed Web of Science ®Google Scholar
• Kumarswamy R, Volkmann I, Thum T. Regulation and function of miRNA-21 in health and disease. RNA Biol. 2011;8:706–713.
   PubMed Web of Science ®Google Scholar
• Hinz B, Phan SH, Thannickal VJ, et al. The myofibroblast: one function, multiple origins. Am J Pathol. 2007;170:1807–1816.
   PubMed Web of Science ®Google Scholar
• Yao Q, Cao S, Li C, et al. Micro-RNA-21 regulates TGF-beta-induced myofibroblast differentiation by targeting PDCD4 in tumor-stroma interaction. Int J Cancer. 2011;128:1783–1792.
   PubMed Web of Science ®Google Scholar
• Jafarinejad-Farsangi S, Farazmand A, Mahmoudi M, et al. MicroRNA-29a induces apoptosis via increasing the Bax:Bcl-2 ratio in dermal fibroblasts of patients with systemic sclerosis. Autoimmunity 2015;48:369–378.
   PubMed Web of Science ®Google Scholar
• Jafarinejad-Farsangi S, Farazmand A, Gharibdoost F, et al. Inhibition of MicroRNA-21 induces apoptosis in dermal fibroblasts of patients with systemic sclerosis. Int J Dermatol. 2016;55:1259–1267.
   PubMed Web of Science ®Google Scholar